Biotech content: a 10-step strategy that simplifies science
Short answer Start with what the law lets you say at your stage. Before approval, explain the science and the trial, but never call the product safe or effective. After approval, every benefit needs its risks beside it. Then write one plain-language source per audience, have a scientist check it, and reuse it across formats.
Want help applying this to your business? Talk it through on a free 30-minute call.
Book a callThe 10 steps at a glance
Biotech content has one job ordinary marketing doesn't: explain hard science to very different readers without saying anything a regulator, an investor's lawyer or a scientist would flag. Do the steps in this order. The first two decide what every later piece may say.
| # | Step | Why it matters in biotech |
|---|---|---|
| 1 | Check what your stage lets you say | FDA and Health Canada rules change at approval |
| 2 | Pick your audiences | Investors, partners, clinicians and patients need different pages |
| 3 | Write one plain-language "source of truth" | Every format draws from the same checked facts |
| 4 | Simplify the words, not the science | The fastest way to lose experts is a claim the data doesn't support |
| 5 | Set up a science and regulatory review | One wrong word can turn education into promotion |
| 6 | Add investor-safe language if you're public | Securities law covers your blog and posts too |
| 7 | Put named experts on every page | Google holds health topics to its highest bar |
| 8 | Research the words each audience searches | A patient and a scientist type different things |
| 9 | Distribute within the ad rules | Google limits ads for unapproved and experimental products |
| 10 | Measure and refresh | Trial results and approvals make old pages wrong |
Step 1: What can a biotech company say before FDA approval?
You may share the science. You may not promote the product. The FDA rule for drugs in clinical trials is direct:
"A sponsor or investigator, or any person acting on behalf of a sponsor or investigator, shall not represent in a promotional context that an investigational new drug is safe or effective for the purposes for which it is under investigation or otherwise promote the drug." (21 CFR 312.7)
The same rule protects scientific exchange: it "is not intended to restrict the full exchange of scientific information concerning the drug, including dissemination of scientific findings in scientific or lay media" (21 CFR 312.7). Investigational medical devices have a matching ban on calling them safe or effective (21 CFR 812.7).
| Your stage | Fine to publish | Don't publish |
|---|---|---|
| Preclinical or in trials (US) | How the science works, trial design, published results, team, milestones | "Safe," "effective," "cures," "breakthrough treatment" about your product |
| Approved prescription drug (US) | Approved uses, with risk information balanced against benefits | Uses or benefits beyond the approved labeling |
| Not yet approved (Canada) | Scientific information, company news | Any advertising of the new drug before a notice of compliance (Food and Drug Regulations, C.08.002) |
| Approved prescription drug (Canada), to the public | Brand name, proper or common name, price and quantity only (C.01.044) | Any other claim |
After US approval, an ad that pushes benefits in "greater scope, depth, or detail" than its side effects lacks "fair balance" (21 CFR 202.1). Promotional pieces for an approved drug must also be filed with the FDA on Form FDA-2253 when first used (21 CFR 314.81).
Enforcement got stricter. In September 2025 the FDA said it was sending "thousands of letters" to drug companies about misleading ads and about 100 cease-and-desist letters, and named "undisclosed paid influencer promotion" as a concern (FDA, September 9, 2025).
Selling a consumer product instead, like a supplement or a home test? The FTC says health claims "require substantiation in the form of competent and reliable scientific evidence" (FTC: Health Products Compliance Guidance).
This is what the rules say, not legal advice. Have regulatory counsel confirm where your product sits.
Step 2: Who is biotech content for?
Usually four groups, and each wants a different page:
| Audience | What they want | Format that fits |
|---|---|---|
| Investors | Market size, milestones, team, risk | Overview page, investor updates |
| Partners and pharma business development | Data, platform, licensing fit | Technical summary, posters, white paper |
| Clinicians and researchers | Mechanism, methods, published results | Publications page, scientific talks |
| Patients and caregivers | What the disease is, how to join a trial | Plain-language explainers, trial page |
Don't write one page for all four. A patient reading your mechanism-of-action page leaves; an investor reading a disease explainer learns nothing.
Step 3: Write one source of truth per topic
Before any blog post, write a one- to two-page plain-language summary of each program: the problem, how your approach works, where it stands, what's proven and what isn't. Your lead scientist approves it once.
Every later piece (a blog post, a LinkedIn carousel, a webinar script, an investor slide) copies facts from that summary. When a trial reads out, you update one file, then the pieces built from it. This is how a five-person team keeps 40 pieces of content from drifting apart.
The summary is also how you stand out. Most competitors say "novel platform." Write the one sentence only you can say: what your approach does that others can't, and the data that shows it.
Step 4: How do you explain complex science simply?
Change the words, keep the claim the same strength. Rules that work:
- Define a term once, in one line. "Antisense oligonucleotide: a short strand of genetic material built to block one faulty protein."
- Give numbers with their base. "12 of 40 patients" says more than "30% response."
- Name the stage every time. "In mice," "in a phase 1 trial of 24 people." Readers assume humans and approval unless told.
- Use one comparison, then stop. A lock and key works once; five analogies confuse.
- Draw what words can't. A simple diagram of the mechanism or the trial timeline does more than a paragraph.
- Say what's unknown. "We don't yet know if the effect lasts" builds more trust with experts than silence.
A useful test: if your lead scientist would wince at the simplified sentence, it changed the science, not just the words.
Step 5: Set up a science and regulatory review
Biotech content needs two checks before it goes live: a scientist for accuracy and someone who knows FDA, Health Canada or FTC rules for wording. Larger drug companies call this medical, legal and regulatory review.
A lean version for a startup:
- Writer drafts from the source of truth.
- A scientist checks every fact against the data or the paper.
- A regulatory reviewer reads for promotional words (Step 1 table).
- Keep the approved version and date. Your log shows who approved what.
Skip it, and one "promising cure" headline can undo a year of careful work.
Step 6: Are you public? Add investor-safe language
If your shares trade publicly, your blog and posts are read by investors, and securities law applies.
- Forward-looking statements. US law gives a safe harbor to a prediction that is "identified as a forward-looking statement, and is accompanied by meaningful cautionary statements" (15 U.S.C. 78u-5). Put that language on pages that talk about timelines or expected results.
- Regulation FD. Material nonpublic news shared with analysts or investors must be made public at the same time if intentional (17 CFR 243.100). A trial readout goes out in a press release or filing first, not in a webinar for a few investors.
- Listed in Canada? Provincial securities law bans "tipping": sharing material news with some people before it is public. National Policy 51-201 explains how this applies to analyst meetings and conferences.
Step 7: Put named experts on every page
Biotech is a health topic, and Google treats health as "Your Money or Your Life." For those topics, Google says its "systems give even more weight to content that aligns with strong E-E-A-T" (experience, expertise, authoritativeness, trust) (Google Search Central).
In practice: a real author or reviewer on each page, a one-line credential ("PhD, molecular biology, 12 years in gene therapy"), a team page with real bios, and links to your publications. More in E-E-A-T for a small business. Using AI to draft is allowed; a scientist checking it matters more here than anywhere (does Google penalize AI content?).
Step 8: What keywords should a biotech company target?
Each audience searches differently, so research each one separately:
| Audience | They search like this |
|---|---|
| Patients | "[disease] new treatment," "[disease] clinical trial near me" |
| Clinicians | "[target] inhibitor phase 2 results," drug class names |
| Partners | "[platform] licensing," "[modality] CDMO" |
| Investors | Your company name, "[disease] pipeline" |
Patient searches have the most volume and the strictest wording limits. Explain the disease and the trial; don't promise results. The free tools and method are in keyword research.
Step 9: Distribute within the ad rules
Organic channels carry most biotech content: LinkedIn for partners and investors, email for updates, conferences and webinars for clinicians. Email to Canadians needs consent first (CASL consent).
Paid ads are tighter. Google doesn't allow ads for speculative or experimental treatments, and limits cell and gene therapies:
"In the United States, Google allows the promotion of FDA licensed or approved cell or gene therapies by entities that hold the relevant FDA license or approval to market that product." (Google Ads Help: Healthcare and medicines policy)
The same policy allows cell or gene therapy ads "that are exclusively educational or informational in nature, regardless of regulatory approval status," and bans clinical trial recruitment ads in most locations (Google Ads Help).
Step 10: Measure and refresh
Track by audience: patient pages by trial inquiries, partner pages by contact requests, investor pages by visits from your name searches. Then set a trigger, not a calendar: every trial readout, approval or label change means reviewing every page that mentions that program. Old phase 1 language on a page after phase 2 results is wrong, and can be misleading. How to decide what to update or remove: content decay.
Example
A 10-person gene therapy startup, preclinical
It publishes a plain-language explainer of the disease, a page on how its vector works "in animal studies," and a team page with PhD bios. Its draft headline "a cure for X" becomes "a new approach to X, now in preclinical testing." It runs no Google ads promoting the therapy, because it isn't FDA-approved, but it posts an educational video on LinkedIn.
A public biotech with a phase 2 readout
Results go out in a press release and filing first. The blog post follows the same day, with forward-looking language at the bottom and "24 of 60 patients" in place of "40% of patients."
A Canadian company with an approved prescription drug
Its public website for patients names the drug, its common name and the price. Treatment claims stay on a section for health professionals, because public ads may say nothing more (C.01.044).
FAQ
Can a biotech startup blog about its drug before approval?
Yes, about the science, the trial and published findings. US rules ban calling an investigational product safe or effective, or promoting it (21 CFR 312.7).
Do scientists have to write the content?
No. A writer can draft it, but a scientist should check every fact before it goes live.
Is a press release about trial results promotion?
Not by itself. Factual results are scientific exchange; words like "safe," "effective" or "breakthrough" about an unapproved product can make it promotion.
Can we run Google Ads for an experimental therapy?
Not to promote it. Google bans ads for speculative and experimental treatments; educational ads about cell or gene therapies are allowed (Google Ads Help).
Different for you?
- You sell health software, not therapies: start with E-E-A-T, and keep product claims to what you can prove.
- You're writing for Canadians by email: CASL consent.
- Your old pages describe outdated results: content decay.
- You want the content and SEO work done: SEO.